Literature DB >> 28845048

The Kaplan-Meier Estimator as an Inverse-Probability-of-Censoring Weighted Average.

Glen A Satten1, Somnath Datta2.   

Abstract

The Kaplan-Meier (product-limit) estimator of the survival function of randomly-censored time-to-event data is a central quantity in survival analysis. It is usually introduced as a nonparametric maximum likelihood estimator, or else as the output of an imputation scheme for censored observations such as redistribute-to-the-right or self-consistency. Following recent work by Robins and Rotnitzky, we show that the Kaplan-Meier estimator can also be represented as a weighted average of identically distributed terms, where the weights are related to the survival function of censoring times. We give two demonstrations of this representation; the first assumes a Kaplan-Meier form for the censoring time survival function, the second estimates the survival functions of failure and censoring times simultaneously and can be developed without prior introduction to the Kaplan-Meier estimator.

Entities:  

Year:  2012        PMID: 28845048      PMCID: PMC5568678          DOI: 10.1198/000313001317098185

Source DB:  PubMed          Journal:  Am Stat        ISSN: 0003-1305            Impact factor:   8.710


  2 in total

1.  Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

Authors:  J M Robins; D M Finkelstein
Journal:  Biometrics       Date:  2000-09       Impact factor: 2.571

2.  Marginal estimation for multi-stage models: waiting time distributions and competing risks analyses.

Authors:  Glen A Satten; Somnath Datta
Journal:  Stat Med       Date:  2002-01-15       Impact factor: 2.373

  2 in total
  15 in total

1.  Simultaneous marginal survival estimators when doubly censored data is present.

Authors:  Olga Julià; Guadalupe Gómez
Journal:  Lifetime Data Anal       Date:  2010-10-01       Impact factor: 1.588

2.  On pseudo-values for regression analysis in competing risks models.

Authors:  Frederik Graw; Thomas A Gerds; Martin Schumacher
Journal:  Lifetime Data Anal       Date:  2008-12-03       Impact factor: 1.588

3.  Generalized Redistribute-to-the-Right Algorithm: Application to the Analysis of Censored Cost Data.

Authors:  Shuai Chen; Hongwei Zhao
Journal:  J Stat Theory Pract       Date:  2013-04-01

4.  Function-based hypothesis testing in censored two-sample location-scale models.

Authors:  Sundarraman Subramanian
Journal:  Lifetime Data Anal       Date:  2018-12-11       Impact factor: 1.588

5.  FASTQuick: rapid and comprehensive quality assessment of raw sequence reads.

Authors:  Fan Zhang; Hyun Min Kang
Journal:  Gigascience       Date:  2021-01-29       Impact factor: 6.524

Review 6.  Testing for center effects on survival and competing risks outcomes using pseudo-value regression.

Authors:  Yanzhi Wang; Brent R Logan
Journal:  Lifetime Data Anal       Date:  2018-07-05       Impact factor: 1.588

7.  Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients.

Authors:  Xiaojuan Li; Stephen R Cole; Abhijit V Kshirsagar; Jason P Fine; Til Stürmer; M Alan Brookhart
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-15       Impact factor: 8.237

8.  Net-benefit regression with censored cost-effectiveness data from randomized or observational studies.

Authors:  Shuai Chen; Jeffrey S Hoch
Journal:  Stat Med       Date:  2022-06-03       Impact factor: 2.497

9.  Evaluating incremental values from new predictors with net reclassification improvement in survival analysis.

Authors:  Yingye Zheng; Layla Parast; Tianxi Cai; Marshall Brown
Journal:  Lifetime Data Anal       Date:  2012-12-20       Impact factor: 1.588

10.  Gone But Not Lost: Implications for Estimating HIV Care Outcomes When Loss to Clinic Is Not Loss to Care.

Authors:  Jessie K Edwards; Catherine R Lesko; Michael E Herce; Gad Murenzi; Christella Twizere; Patricia Lelo; Kathryn Anastos; Olga Tymejczyk; Marcel Yotebieng; Denis Nash; Adebola Adedimeji; Andrew Edmonds
Journal:  Epidemiology       Date:  2020-07       Impact factor: 4.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.